Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25077376 | 1.00 | CNR1 (0.39) | CNR1CNR2MGLLGRM2PLA2G4B | |
| SCHEMBL25763089 | 0.90 | ACACB (0.39) | CNR1CNR2MGLLGRM2PLA2G4B | |
| SCHEMBL29193321 | 0.86 | PLA2G4B (0.40) | PLA2G4BSMPD1 | |
| SCHEMBL29193196 | 0.86 | PLA2G4B (0.40) | PLA2G4BSMPD1 | |
| SCHEMBL24304936 | 0.86 | PLA2G4B (0.40) | PLA2G4BSMPD1 | |
| SCHEMBL30825807 | 0.86 | PLA2G4B (0.40) | PLA2G4BSMPD1 | |
| SCHEMBL30825796 | 0.86 | PLA2G4B (0.40) | PLA2G4BSMPD1 | |
| SCHEMBL25077154 | 0.81 | EPAS1 (0.35) | CNR2MGLL | |
| SCHEMBL30259763 | 0.81 | EPAS1 (0.35) | CNR2MGLL | |
| SCHEMBL25284493 | 0.81 | EPAS1 (0.35) | CNR2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | PHOSPHO1, SGMS1, SGMS2 | CNR1 1529/4885CNR2 1754/4885MGLL 55/4885 |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | CNR1 1529/4885CNR2 1754/4885MGLL 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.